Using our Cell-Kro biologic grafting drug, we are grafting patented human cardiac progenitor cells to improve cardiac repair and function after myocardial infarction (MI, heart attack).
Simple and effective grafting tool that enhances adhesion, survival, proliferation, migration, and differentiation of transplanted stem/progenitor cells. Priming cells with Cell-Kro for 30 min on ice prior to injection provides robust, long-term engraftment (i.e. graft success).
About Our Solutions
Cell-Kro
No treatments that preserve or replace damaged tissue after myocardial infarction (MI) currently exist and poor graft success is a common problem after transplantation of cultured cells into injured tissues. Cell grafts after ischemic injuries, such as MI, are especially inefficient due to low adhesion to host tissue, low cell survival rates and low levels of migration.
Cell-Kro is a connective tissue growth factor (CTGF-D4) and insulin combo that primes reparative cells for successful engraftment and survival. Short term incubation of cardiac progenitor cells in Cell-Kro prior to transplantation in a rat model of MI promoted robust, sub-epicardial engraftment, survival and migration of cell derivatives one week after MI. One-month studies showed rebuilt blood vessels and a reduced negative remodeling. Cell-Kro is a powerful tool that remarkably promotes graft success and lasting cell replacement.
Priming cells with Cell-Kro markedly increases graft success
Cell-Kro Achievements
Screening/Identification of Biologic
Cell-Kro [CTGF-D4/Insulin]
Proven Efficacy in Vivo
Grafts improve cardiac function after MI
Patented Cells
Human epicardial cardiac progenitor cells
Defined Mechanism of Action
Identified receptor for CTGF-D4
Strong Clinical Feasibility
Using Cell-Kro is both fast and easy
Pre-clinical Testing
Cell-Kro grafts human cells to pigs with MI